32 results
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
2 Apr 21
Agios Announces Closing of Oncology Business Sale to Servier
4:47pm
future as we seek to rapidly advance our genetically defined disease portfolio, delivering sustainable, long-term value to shareholders and superior
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
, advance multiple pivotal studies across thalassemia, sickle cell disease and pediatric pyruvate kinase deficiency, and build a sustainable pipeline
DEFA14A
AGIO
Agios Pharmaceuticals Inc
12 Jan 21
Additional proxy soliciting materials
5:15pm
of at least five molecules in at least ten indications in genetically-defined diseases, as well as a sustainable, robust research pipeline that can deliver … the potential to be a blockbuster drug out of the gate, and allow us to generate more resources in the future to continue a highly sustainable business model
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
5 May 22
Agios Reports Business Highlights and First Quarter 2022 Financial Results
7:21am
and Governance (ESG) Report disclosing ESG initiatives and metrics aligned with the United Nations Sustainable Development Goals (UN SDGs) and the standards
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
11 Jan 21
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
7:14am
and sustainable research pipeline. As we reimagine the future of Agios, we look forward to building on our core values and pioneering leadership in cellular
8-K
EX-99.1
efrok2im mm
2 Aug 18
Agios Reports Second Quarter 2018 Financial Results
7:28am
8-K
EX-99.1
6us1n
4 May 18
Results of Operations and Financial Condition
7:07am
DEFA14A
EX-99.1
2ur7ybxwvm 0dmtox
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.1
rf24o43o
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
r6qibs8fa1e1jm42
1 Nov 18
Agios Reports Third Quarter 2018 Financial Results
7:45am
8-K
EX-99.1
00e j6fcf8sh8sd1uo
20 Jul 18
FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients
11:21am
DEFA14A
x81ul 432ydn9n0n
11 Jan 21
Additional proxy soliciting materials
7:17am
8-K
EX-99.2
u8q2a
21 Dec 20
Regulation FD Disclosure
7:04am
DEFA14A
EX-99.2
psovwelc cu7g
21 Dec 20
Additional proxy soliciting materials
7:10am
DEFA14A
1j2avys4lxa 59
21 Dec 20
Additional proxy soliciting materials
5:23pm
8-K
EX-99.1
g0b 9eh8kt0ca
16 Oct 15
Regulation FD Disclosure
12:00am
8-K
EX-99.2
kv3xz 65y04q8f
4 May 18
Results of Operations and Financial Condition
7:07am